Top Page
China Traditional Chinese Medicine Holdings Co
(0570)
China Traditional Chinese Medicine Holdings Co (0570) vs. iShares MSCI Hong Kong ETF (EWH)
China Traditional Chinese Medicine Holdings Co Business Overview & Revenue Model
China Traditional Chinese Medicine Holdings Co Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 15.59B | 16.51B | 18.12B | 14.30B | 19.05B | 14.81B |
| Gross Profit | 7.43B | 7.86B | 9.27B | 7.20B | 11.83B | 9.13B |
| EBITDA | 1.64B | 1.82B | 2.56B | 2.16B | 3.59B | 3.16B |
| Net Income | -264.83M | 54.07M | 1.29B | 764.49M | 1.93B | 1.66B |
Balance Sheet | ||||||
| Total Assets | 34.53B | 35.06B | 37.07B | 35.62B | 36.39B | 33.09B |
| Cash, Cash Equivalents and Short-Term Investments | 5.27B | 5.34B | 3.69B | 3.46B | 4.14B | 5.03B |
| Total Debt | 3.60B | 4.02B | 5.16B | 5.04B | 5.06B | 5.22B |
| Total Liabilities | 11.13B | 11.13B | 13.13B | 12.67B | 13.73B | 12.19B |
| Stockholders Equity | 20.70B | 21.20B | 21.16B | 20.17B | 19.72B | 18.06B |
Cash Flow | ||||||
| Free Cash Flow | -343.51M | 2.07B | 680.20M | 565.09M | -81.17M | -1.02B |
| Operating Cash Flow | -569.70M | 2.58B | 1.17B | 1.09B | 796.03M | 228.47M |
| Investing Cash Flow | 165.25M | -379.24M | -477.62M | -374.15M | -536.94M | -1.07B |
| Financing Cash Flow | -47.07M | -1.39B | -584.31M | -557.28M | -724.32M | -1.01B |
China Traditional Chinese Medicine Holdings Co Technical Analysis
China Traditional Chinese Medicine Holdings Co Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | HK$6.90B | 2.21 | 10.85% | 5.80% | -20.64% | -25.39% | |
72 Outperform | HK$13.38B | 4.45 | 25.92% | 3.93% | 19.05% | 13.68% | |
58 Neutral | HK$10.06B | 35.32 | 7.48% | 4.47% | 1.65% | -16.38% | |
54 Neutral | HK$9.87B | -23.52 | -1.26% | 3.66% | -9.58% | -128.83% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | HK$13.72B | 22.81 | -1.87% | 0.87% | 19.21% | -115.91% |
China Traditional Chinese Medicine Holdings Co Corporate Events
China Traditional Chinese Medicine Holdings Co. Limited announced that all resolutions put to shareholders at its extraordinary general meeting on 2 February 2026 were duly passed by poll. Shareholders approved, confirmed and ratified the company’s 2026–2028 Financial Services Framework Agreement, as well as new Master Purchase and Master Supply Agreements and their respective annual caps for the three financial years ending 31 December 2028, despite major shareholder CNPGC and its associates abstaining from voting on the relevant resolutions. The strong support for the purchase and supply arrangements, with approval rates around 99%, provides the group with formally sanctioned frameworks for intra-group financial services and trading activities over the next three years, underpinning operational continuity and related-party transactions in line with Hong Kong listing requirements.
The most recent analyst rating on (HK:0570) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on China Traditional Chinese Medicine Holdings Co stock, see the HK:0570 Stock Forecast page.
China Traditional Chinese Medicine Holdings has issued a profit warning, flagging that it expects to swing from a small net profit of about RMB20.77 million in 2024 to a net loss of between RMB350 million and RMB500 million for the year ended 31 December 2025, while adjusted net profit is projected to fall by 45%–55% from RMB635.54 million. Management attributes the deterioration mainly to weaker revenue scale and profitability in its concentrated TCM granules business amid a higher share of centralized procurement and intensified competition, as well as increased goodwill, intangible asset and credit impairments, but stresses that the adjustments are largely non-operating or non-recurring and are not expected to undermine the group’s ongoing operations, with full audited results to follow by end-March 2026.
The most recent analyst rating on (HK:0570) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on China Traditional Chinese Medicine Holdings Co stock, see the HK:0570 Stock Forecast page.
China Traditional Chinese Medicine Holdings Co. Limited has convened an extraordinary general meeting for 2 February 2026 in Foshan to seek shareholder approval for a series of three-year framework agreements covering financial services, procurement and product supply for the period 2026–2028. The resolutions, if passed, will ratify a financial services framework with Sinopharm Group Finance, as well as master purchase and master supply agreements with China National Pharmaceutical Group Co., Ltd. and its subsidiaries, and will authorise directors to implement these arrangements and make non-material amendments, thereby formalising ongoing related-party transactions that underpin the company’s financing, sourcing of TCM and chemical materials, and sales and leasing activities within the Sinopharm Group.
The most recent analyst rating on (HK:0570) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on China Traditional Chinese Medicine Holdings Co stock, see the HK:0570 Stock Forecast page.
China Traditional Chinese Medicine Holdings Co. has scheduled an extraordinary general meeting (EGM) for 2 February 2026 to seek shareholder approval for the renewal of certain continuing connected transaction agreements and the transactions contemplated under them. To determine shareholders’ eligibility to attend and vote, the company will close its register of members from 28 January to 2 February 2026, during which no share transfers will be registered, and it has set 27 January 2026 as the deadline for lodging transfer documents, with a circular, EGM notice and proxy form to be dispatched to shareholders in due course, underscoring the company’s ongoing governance processes and regulatory compliance in managing related-party dealings.
The most recent analyst rating on (HK:0570) stock is a Sell with a HK$1.60 price target. To see the full list of analyst forecasts on China Traditional Chinese Medicine Holdings Co stock, see the HK:0570 Stock Forecast page.
China Traditional Chinese Medicine Holdings Co. Limited has announced a delay in sending to shareholders a circular relating to the renewal of certain continuing connected transactions. The circular, which will include details of the transaction agreements, recommendations from the Independent Board Committee, and advice from the Independent Financial Adviser, was originally expected to be dispatched around 16 December 2025 but will now be sent on or before 15 January 2026, as the company needs more time to prepare and finalise the required information; the postponement slightly extends the timetable for shareholder review and approval at the forthcoming extraordinary general meeting but does not alter the substance of the proposed transactions.
The most recent analyst rating on (HK:0570) stock is a Sell with a HK$1.60 price target. To see the full list of analyst forecasts on China Traditional Chinese Medicine Holdings Co stock, see the HK:0570 Stock Forecast page.
China Traditional Chinese Medicine Holdings Co. Limited announced a change in its board committee composition, with Mr. Liu Haijian being re-designated as a member of the Remuneration and Evaluation Committee, effective November 26, 2025. This strategic move is expected to enhance the company’s corporate governance by aligning its remuneration system with long-term performance goals and shareholder value growth, thereby improving decision-making quality and management precision.
The most recent analyst rating on (HK:0570) stock is a Sell with a HK$1.60 price target. To see the full list of analyst forecasts on China Traditional Chinese Medicine Holdings Co stock, see the HK:0570 Stock Forecast page.
China Traditional Chinese Medicine Holdings Co. Limited has announced the composition of its board of directors, detailing the roles and functions of each member. This update provides transparency in governance and may impact the company’s strategic direction and decision-making processes, potentially affecting stakeholders’ interests and the company’s position within the traditional Chinese medicine industry.
The most recent analyst rating on (HK:0570) stock is a Sell with a HK$1.60 price target. To see the full list of analyst forecasts on China Traditional Chinese Medicine Holdings Co stock, see the HK:0570 Stock Forecast page.
China Traditional Chinese Medicine Holdings Co. Limited has announced the renewal of three key agreements with Sinopharm Group Finance and CNPGC for the period from 2026 to 2028. These agreements include the Financial Services Framework Agreement, the Master Purchase Agreement, and the Master Supply Agreement, which involve financial services, material purchases, and product sales. The transactions are classified as continuing connected transactions under Hong Kong’s listing rules, requiring compliance with specific regulatory requirements. This renewal is expected to strengthen the company’s financial operations and supply chain, enhancing its market position and benefiting stakeholders.
The most recent analyst rating on (HK:0570) stock is a Sell with a HK$1.60 price target. To see the full list of analyst forecasts on China Traditional Chinese Medicine Holdings Co stock, see the HK:0570 Stock Forecast page.
China Traditional Chinese Medicine Holdings Co. Limited has entered into a New Financial Services (2025) Framework Agreement with Sinopharm Group Finance, effective from November 19, 2025, to December 31, 2025. This agreement, which includes deposit, loan, and other financial services, is designed to continue the financial relationship between the two entities. The agreement’s terms are similar to a previous arrangement set to expire, and it ensures that financial services are provided on favorable terms without requiring additional security from the company. The announcement highlights the company’s strategic financial planning and its implications for maintaining operational stability and compliance with listing rules.
The most recent analyst rating on (HK:0570) stock is a Sell with a HK$1.60 price target. To see the full list of analyst forecasts on China Traditional Chinese Medicine Holdings Co stock, see the HK:0570 Stock Forecast page.